Skip to content
Screener

Relay Therapeutics, Inc. RLAY Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

PVL
Palvella TherapeuticsPVLA
-$15.76M-92.3%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$649.7M-162%
Immunome logo
ImmunomeIMNM
-$73.46M-69.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$96.76M-31.3%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$46.14M-11.6%
Regenxbio logo
RegenxbioRGNX
$22.7M+132%

Other financials

Income statement

See full
Revenue$350.0K-48.3%
Operating income-$90.8M-18.2%
Net income-$83.7M-18.9%
EPS (diluted)-$0.410.0%

Balance sheet

See full
Cash & equivalents$121.2M+6.4%
Total debt$30.7M-10.3%
Total equity$890.0M+33.7%
Total assets$967.5M+32.7%

Cash flow

See full
Operating cash flow-$54.1M+2.1%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$4.33B+673%
Enterprise value$4.24B+783%
P/S418.6×+352×

Profitability

See full
Operating margin-2,999.4%-637pp
Net margin-2,763.6%-568pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-36.8%-6.3pp
Debt / equity0.0×
Current ratio18.3×-2.7×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income, net7,1176,47212,41614,277
Net loss$(83,707)$(70,375)$(156,998)$(147,440)
Net loss per share, basic and diluted$(0.41)$(0.41)$(0.82)$(0.87)
Weighted average shares of common stock, basic and diluted202,849,466171,264,622191,412,839170,254,500
Other comprehensive (loss) income:
Unrealized holding (loss) gain(1,381)(201)(2,286)828
Total other comprehensive (loss) income(1,381)(201)(2,286)828
Total comprehensive loss$(85,088)$(70,576)$(159,284)$(146,612)

Item 1. Financial Statements.

FAQ

What is Relay Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Relay Therapeutics, Inc. (RLAY) reported comprehensive income (loss), net of tax, attributable to parent of -$85.09M in Q2 2026.
How has Relay Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Relay Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 20.6% year-over-year, from -$70.58M to -$85.09M.
What is the long-term trend for Relay Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -6.9% compound annual growth rate (CAGR), from -$365.02M to -$274.76M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from all sources, combining net income with other comprehensive income items. It provides a comprehensive view of the company's total financial performance and the impact of non-operating factors on shareholder equity. Investors use this to understand the full scope of value creation or erosion beyond the standard net income figure.

Ask your AI about Relay Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude